Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06419894

Advanced Cardiac Magnetic Resonance Imaging for Assessment of Obstructive Coronary Artery Disease: ADVOCATE-CMR

Stress perfusion cardiovascular magnetic resonance (CMR) imaging is an established non-invasive imaging test for detection of obstructive coronary artery disease (CAD). Fully automated quantitative perfusion CMR (QP CMR) is a new technical advancement, which offers measurement of myocardial blood flow in CMR. Additionally, recent innovations have introduced various contrast-agent-free methods for CAD assessment, such as stress T1 mapping reactivity (∆T1) and oxygen-sensitive CMR (OS CMR). These methods might eliminate the necessity for contrast administration in clinical practice, simplifying, reducing time, invasiveness and costs in evaluating patients with suspected obstructive CAD. The ADVOCATE-CMR study aims to validate QP CMR, ∆T1 and OS CMR imaging against invasive fractional flow reserve (FFR) for detection of obstructive CAD. The study also aims to head-to-head compare the diagnostic accuracy of these CMR techniques with the conventional visual assessment of stress perfusion CMR and to correlate them to short- and long-term clinical outcomes.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

About this study

Study design: Single-center, observational, prospective, cross-sectional cohort study performed at the Amsterdam University Medical Centers - Location VUmc.

Study population: 182 symptomatic patients with suspected obstructive CAD (without a previous CAD history), scheduled for invasive coronary angiography (ICA) according to the decision of the treating clinician.

Methods:

  • CMR image acquisition prior to clinically scheduled ICA, using the following pulse sequences: cine imaging, OS-CMR with breathing maneuvers, adenosine-stress and rest T1 mapping, adenosine-stress and rest QP-CMR, late gadolinium enhancement;
  • Fractional flow reserve (FFR), instantaneous wave-free ratio (iFR), ratio between proximal and distal coronary pressures over entire resting cycle period (Pd/Pa ratio), coronary flow reserve (CFR) and index of microcircular resistance (IMR) in all main coronary arteries during ICA;
  • Follow-up CMR according to the abovementioned protocol 3 months after ICA (or 3 months after revascularization, if performed separately more than 1 day following ICA);
  • Clinical follow-up - 3, 6 months, 1 and 3 years after ICA or revascularization (if performed separately more than 1 day following ICA)

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspected obstructive coronary artery disease
  • No documented prior history of coronary artery disease
  • Clinical referral for invasive coronary angiography according to the referring clinician's decision
  • Competent adult (age ≥18 years)
  • Signed informed consent

Exclusion criteria

  • Acute coronary syndrome
  • History of coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting surgery)
  • History of coronary artery disease or acute coronary syndrome (myocardial infarction, unstable angina)
  • Use of sildenafil or dipyridamole that cannot be terminated
  • Pregnancy or lactation
  • Allergic reaction to iodized contrast
  • Concurrent or prior (within last 30 days) participation in other research studies using interventional drugs
  • Extensive comorbidities (i.e. cancer, other severe chronic diseases)
  • Contraindication for cardiac magnetic resonance with gadolinium-based contrast agent (including severe claustrophobia, magnetic resonance unsafe implants/devices or MR conditional devices not suitable for 3T scanner, severe renal failure with estimated glomerular filtration rate<30 mL/min/1,73 m2, known hypersensitivity for gadolinium-based contrast agent)
  • Contraindications for adenosine usage (including hypersensitivity to adenosine/dipyridamole/regadenoson, second or third degree atrio-ventricular block, sick sinus syndrome, sinus bradycardia (heart rate <40 bpm), long QT syndrome, severe hypertension (> 220/120 mmHg), systolic blood pressure <90mmHg, concomitant use of dipyridamole, severe asthma or severe chronic obstructive pulmonary disease)

Treatment and study plan

Primary outcomes

  1. Diagnostic accuracy of QP CMR (stress myocardial blood flow [MBF], stress relative MBF [rMBF], myocardial perfusion reserve [MPR] and relative MPR [rMPR]) to detect obstructive CAD, as defined by FFR

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, area under the curve (AUC), positive predictive value (PPV), negative predictive value (NPV)

Secondary outcomes

  1. Diagnostic accuracy of ΔT1 to detect obstructive CAD, as defined by FFR

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  2. Diagnostic accuracy of OS CMR (breathing-induced myocardial oxygenation reserve; B-MORE) to detect obstructive CAD, as defined by FFR

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  3. Head-to-head comparison of diagnostic accuracies of QP CMR (stress MBF, stress rMBF, MPR, rMPR), ΔT1, OS CMR (B-MORE) and conventional visual assessment of GBCA-based first pass perfusion imaging to detect obstructive CAD, as defined by FFR

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  4. Diagnostic accuracy of QP CMR (stress MBF, stress rMBF, MPR and rMPR) to detect obstructive CAD, as defined by iFR and resting Pd/Pa

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  5. Diagnostic accuracy of ΔT1 to detect obstructive CAD, as defined by iFR and resting Pd/Pa

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  6. Diagnostic accuracy of OS CMR (B-MORE) to detect obstructive CAD, as defined by iFR and resting Pd/Pa

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  7. Head-to-head comparison of diagnostic accuracies of QP CMR (stress MBF, stress rMBF, MPR, rMPR), ΔT1, OS CMR (B-MORE) and conventional visual assessment of first pass perfusion imaging to detect obstructive CAD, as defined by iFR and resting Pd/Pa

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  8. Relation of stress and rest MBF and rMBF, MPR and rMPR, ΔT1 and B-MORE to Seattle Angina Questionnaire (SAQ)-7 Summary score

    Time frame: Before ICA and 3, 6 months, 1 and 3 years after the ICA (or revascularization if applicable)

  9. Relation of stress and rest MBF and rMBF, MPR and rMPR, ΔT1 and B-MORE to SAQ-7 Angina Frequency score

    Time frame: Before ICA and 3, 6 months, 1 and 3 years after the ICA (or revascularization if applicable)

  10. Relation of stress and rest MBF and rMBF, MPR and rMPR, ΔT1 and B-MORE to SAQ-7 Physical Limitation score

    Time frame: Before ICA and 3, 6 months, 1 and 3 years after the ICA (or revascularization if applicable)

  11. Relation of stress and rest MBF and rMBF, MPR and rMPR, ΔT1 and B-MORE to SAQ-7 Quality of Life score

    Time frame: Before ICA and 3, 6 months, 1 and 3 years after the ICA (or revascularization if applicable)

  12. Relation of stress and rest MBF and rMBF, MPR and rMPR, ΔT1 and B-MORE to Rose Dyspnea Scale score

    Time frame: Before ICA and 3, 6 months, 1 and 3 years after the ICA (or revascularization if applicable)

  13. Prognostic value of QP CMR (stress MBF, stress rMBF, MPR and rMPR), stress T1 mapping reactivity and OS CMR (B-MORE)

    Time frame: 3 months, 6 months, 1 year, 3 years

    • Composite of cardiovascular (CV) death (death resulting from an acute myocardial infarction, sudden cardiac death, death due to heart failure, stroke, CV procedures, CV hemorrhage, other CV causes), myocardial infarction (according ESC/ACCF/AHA/WHF 4th Universal Definition of Myocardial Infarction), ischemia-driven coronary revascularization (all coronary revascularization performed in the context of myocardial infarction and those for worsening symptoms in combination with evidence of myocardial ischemia) or stroke (acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction);
    • Composite of myocardial infarction or ischemia-driven coronary revascularization;
    • Composite of cardiovascular death, stroke or myocardial infarction;
    • Myocardial infarction;
    • Ischemia-driven coronary revascularization;
    • Stroke;
    • Death from any cause;
    • CV death

Other outcomes

  1. Diagnostic accuracies of QP CMR (stress MBF, stress rMBF, MPR and rMPR), ΔT1 and B-MORE to detect microvascular dysfunction (MVD), as defined by CFR

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  2. Diagnostic accuracy of QP CMR (stress MBF, stress rMBF, MPR and rMPR), ΔT1 and B-MORE to differentiate between MVD (as defined by CFR) and 3-vessel obstructive CAD

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Sensitivity, specificity, accuracy, AUC, PPV, NPV

  3. Change in stress MBF after revascularization

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Difference between stress MBF before revascularization (baseline) and after revascularization (in ml/g/min)

  4. Change in MPR after revascularization

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Difference between MPR before revascularization (baseline) and after revascularization

  5. Change in stress T1 mapping after revascularization

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Difference between stress T1 mapping before revascularization (baseline) and after revascularization (in ms)

  6. Change in ΔT1 after revascularization

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Difference between ΔT1 before revascularization (baseline) and after revascularization

  7. Change in B-MORE after revascularization

    Time frame: ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

    Difference between B-MORE before revascularization (baseline) and after revascularization (in %)

  8. Costs of QP CMR, stress T1 mapping reactivity and OS CMR compared to ICA

    Time frame: CMR and following ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

  9. Procedural time of QP CMR, stress T1 mapping reactivity and OS CMR compared to ICA

    Time frame: CMR and following ICA + hemodynamic measurements within 6 weeks of the initial CMR scan

Sponsors and collaborators

Lead sponsor

Amsterdam UMC, location VUmc

Other

Registry information

Acronym: ADVOCATE-CMR

Important dates

Study start
2024
Primary completion
2033
Study completion
2033
First posted
May 17, 2024
Registry last updated
Nov 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.